Home › Ariad Pharma Discontinues Phase III Trial of Ponatinib (Iclusig) in Leukemia Patients
 

Keywords :   


Ariad Pharma Discontinues Phase III Trial of Ponatinib (Iclusig) in Leukemia Patients

2013-10-20 13:07:47| Biotech - Topix.net

Ariad Pharmaceuticals, Inc. has announced that it is discontinuing the phase III EPIC trial of ponatinib in patients with newly diagnosed chronic myeloid leukemia .

Tags: iii trial phase patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11 EVA 6
23.11 8
23.11SEVENTEEN ALWAYS YOURS Weverse 13
23.11 DX
23.11 No.23/1998
23.11 DVD 9
23.11
23.11 CD His Melody
More »